AI Engines For more Details: Perplexity Kagi Labs You
Antipsychotic Effects: Molindone hydrochloride exerts its therapeutic effects by blocking dopamine receptors in the brain, particularly dopamine D2 receptors. By inhibiting dopamine activity, molindone helps alleviate psychotic symptoms such as hallucinations, delusions, disorganized thinking, and agitation associated with schizophrenia and other psychotic disorders.
Management of Positive Symptoms: Molindone hydrochloride is effective in managing positive symptoms of schizophrenia, which include hallucinations (perceiving things that are not real), delusions (false beliefs), and thought disorders. It helps reduce the severity and frequency of these symptoms, improving overall functioning and quality of life in affected individuals.
Minimal Sedative Effects: Compared to some other antipsychotic medications, molindone hydrochloride is associated with minimal sedative effects. This can be advantageous for patients who need to remain alert and functional during the day while receiving treatment for schizophrenia. However, individual responses to medications may vary, and some patients may experience sedation or drowsiness with molindone.
Extrapyramidal Symptoms: Like other antipsychotic medications, molindone hydrochloride can cause extrapyramidal symptoms (EPS), which include muscle stiffness, tremors, restlessness, and abnormal involuntary movements such as tardive dyskinesia. The risk of EPS is generally lower with molindone compared to typical antipsychotics, but it still requires monitoring, especially at higher doses.
Orthostatic Hypotension: Molindone hydrochloride may cause orthostatic hypotension, a drop in blood pressure upon standing up from a sitting or lying position. This can lead to dizziness, lightheadedness, and fainting. Patients should be advised to rise slowly from a lying or sitting position to minimize the risk of falls.
Anticholinergic Effects: Molindone hydrochloride may produce anticholinergic side effects such as dry mouth, constipation, blurred vision, and urinary retention. These effects are due to its antagonistic action on muscarinic acetylcholine receptors and may contribute to discomfort or inconvenience for some patients.
Metabolic Effects: Antipsychotic medications, including molindone hydrochloride, may be associated with metabolic side effects such as weight gain, dyslipidemia (abnormal levels of lipids in the blood), and glucose intolerance. Regular monitoring of metabolic parameters is recommended, and interventions such as lifestyle modifications or adjunctive medications may be necessary to manage metabolic disturbances.
Psychological and Neurological Effects: Some patients may experience psychological or neurological side effects such as anxiety, depression, agitation, insomnia, or cognitive impairment while taking molindone hydrochloride. Close monitoring and communication with a healthcare provider are essential to address any emerging symptoms and optimize treatment outcomes.
Adverse Reactions: Rare but serious adverse reactions associated with antipsychotic use, including molindone hydrochloride, may include neuroleptic malignant syndrome (NMS), a potentially life-threatening condition characterized by fever, muscle rigidity, altered mental status, and autonomic dysfunction. Prompt recognition and management of NMS are critical to prevent complications.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 2.1 | 2.1 | |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 2.3 | 1.1 | 1.09 |
| Allergies | 2.2 | 1 | 1.2 |
| Allergy to milk products | 0.5 | 1.6 | -2.2 |
| Alopecia (Hair Loss) | 0.7 | 0.7 | |
| Alzheimer's disease | 2.4 | 2.6 | -0.08 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1 | 0.2 | 4 |
| Ankylosing spondylitis | 2.6 | 1 | 1.6 |
| Anorexia Nervosa | 1 | 1.2 | -0.2 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.7 | |
| Asthma | 2.9 | 1.8 | 0.61 |
| Atherosclerosis | 1.2 | 0.7 | 0.71 |
| Atrial fibrillation | 1.7 | 1.6 | 0.06 |
| Autism | 3.5 | 4.1 | -0.17 |
| Autoimmune Disease | 1.2 | 0.8 | 0.5 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.7 | 1.7 | |
| Bipolar Disorder | 1.3 | 0.8 | 0.63 |
| Brain Trauma | 0.6 | 1.1 | -0.83 |
| Breast Cancer | 0.5 | 0.5 | |
| Cancer (General) | 0.6 | 0.1 | 5 |
| Carcinoma | 2.5 | 1 | 1.5 |
| Celiac Disease | 1.3 | 1.3 | 0 |
| Cerebral Palsy | 1.2 | 0.8 | 0.5 |
| Chronic Fatigue Syndrome | 2.2 | 1.8 | 0.22 |
| Chronic Kidney Disease | 2 | 0.5 | 3 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.9 | 1.4 | 0.36 |
| Chronic Urticaria (Hives) | 1.4 | 0.1 | 13 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 0.8 | 0.88 |
| Cognitive Function | 1.3 | 1.1 | 0.18 |
| Colorectal Cancer | 4.5 | 1.3 | 2.46 |
| Constipation | 0.9 | 0.5 | 0.8 |
| Coronary artery disease | 1.5 | 1.2 | 0.25 |
| COVID-19 | 2.9 | 2.8 | 0.04 |
| Crohn's Disease | 4.8 | 2 | 1.4 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.8 | 1.2 | -0.5 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 1.2 | 1.1 | 0.09 |
| Denture Wearers Oral Shifts | 1.3 | 1.3 | |
| Depression | 4.2 | 2.9 | 0.45 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.8 | 1.4 | 0.29 |
| Endometriosis | 2.1 | 1.1 | 0.91 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 2.1 | 1 | 1.1 |
| erectile dysfunction | 1.2 | 0.3 | 3 |
| Fibromyalgia | 1.3 | 0.7 | 0.86 |
| Functional constipation / chronic idiopathic constipation | 2.4 | 1.7 | 0.41 |
| gallstone disease (gsd) | 2 | 1.1 | 0.82 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1 | 0.3 | 2.33 |
| Generalized anxiety disorder | 2.1 | 0.9 | 1.33 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.6 | |
| Graves' disease | 1.3 | 1.7 | -0.31 |
| Gulf War Syndrome | 0.3 | 0.4 | -0.33 |
| Halitosis | 1.4 | 0.3 | 3.67 |
| Hashimoto's thyroiditis | 1.8 | 0.6 | 2 |
| Heart Failure | 2.5 | 0.8 | 2.13 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.8 | 0.3 | 1.67 |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
| hyperglycemia | 1.5 | 1 | 0.5 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypertension (High Blood Pressure | 1.9 | 1.6 | 0.19 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 1.8 | 0.3 | 5 |
| IgA nephropathy (IgAN) | 1.3 | 1.8 | -0.38 |
| Inflammatory Bowel Disease | 4.1 | 3.2 | 0.28 |
| Insomnia | 1.5 | 1.4 | 0.07 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 1 | 1 | |
| Irritable Bowel Syndrome | 3.4 | 2.3 | 0.48 |
| ischemic stroke | 1.8 | 1.4 | 0.29 |
| Liver Cirrhosis | 4.1 | 2.2 | 0.86 |
| Long COVID | 2.8 | 1.9 | 0.47 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.6 | 0.6 | |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.2 | 0.3 | 3 |
| ME/CFS with IBS | 0.3 | 0.6 | -1 |
| ME/CFS without IBS | 0.7 | 1.2 | -0.71 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.4 | 0.5 | -0.25 |
| Metabolic Syndrome | 3.4 | 2.8 | 0.21 |
| Mood Disorders | 4.1 | 2.7 | 0.52 |
| multiple chemical sensitivity [MCS] | 1.2 | 1.2 | |
| Multiple Sclerosis | 2.7 | 2.6 | 0.04 |
| Multiple system atrophy (MSA) | 0.2 | 0.3 | -0.5 |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 1.3 | -1.3 | |
| Neuropathy (all types) | 0.3 | 1.6 | -4.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.2 | 1.2 | 0.83 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.6 | 0 |
| Obesity | 3.3 | 3.6 | -0.09 |
| obsessive-compulsive disorder | 2.4 | 1.2 | 1 |
| Osteoarthritis | 1.7 | 0.9 | 0.89 |
| Osteoporosis | 1.7 | 0.6 | 1.83 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 3.4 | 2.8 | 0.21 |
| Polycystic ovary syndrome | 3.9 | 1.4 | 1.79 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.3 | 0.4 | -0.33 |
| primary biliary cholangitis | 0.6 | 0.7 | -0.17 |
| Primary sclerosing cholangitis | 1.9 | 1.5 | 0.27 |
| Psoriasis | 1.2 | 1.9 | -0.58 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.1 | 1.8 | 0.72 |
| Rosacea | 0.3 | 0.5 | -0.67 |
| Schizophrenia | 2.2 | 1.8 | 0.22 |
| scoliosis | 0.2 | 0.2 | |
| Sjögren syndrome | 1.7 | 1.2 | 0.42 |
| Sleep Apnea | 0.6 | 0.8 | -0.33 |
| Slow gastric motility / Gastroparesis | 0.8 | 0.3 | 1.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 1.4 | |
| Stress / posttraumatic stress disorder | 2.1 | 1.6 | 0.31 |
| Systemic Lupus Erythematosus | 2.7 | 0.8 | 2.38 |
| Tic Disorder | 0.3 | 0.3 | 0 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 1.6 | 1.5 | 0.07 |
| Type 2 Diabetes | 3.4 | 3 | 0.13 |
| Ulcerative colitis | 2.8 | 1.8 | 0.56 |
| Unhealthy Ageing | 1.9 | 1.3 | 0.46 |
| Vitiligo | 1.4 | 0.7 | 1 |
